|
1）Sugiyama H, Yokoyama H, Sato H, et al. Japan Renal Biopsy Registry and Japan Kidney Disease Registry: Committee Report for 2009 and 2010. Clin Exp Nephrol. 2013; 17: 155-73
|
|
|
|
2）Jin DC. Dialysis registries in the world: Korean Dialysis Registry. Kidney Int Suppl (2011). 2015; 5: 8-11
|
|
|
|
|
|
3）Prischl FC, Auinger M, Saemann M, et al. Diabetes-related end-stage renal disease in Austria 1965-2013. Nephrol Dial Transplant. 2015; 30: 1920-7
|
|
|
|
|
|
4）Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015; 38: 954-62
|
|
|
|
|
|
5）Haneda M, Utsunomiya K, Koya D, et al. A new classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy. Clin Exp Nephrol. 2015; 19: 1-5
|
|
|
|
|
|
6）Wada T, Haneda M, Furuichi K, et al. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014; 18: 613-20
|
|
|
|
|
|
7）Shimizu M, Furuichi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013; 36: 3655-62
|
|
|
|
|
|
8）Toyama T, Furuichi K, Ninomiya T, et al. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. PLoS One. 2013; 8: e71810
|
|
|
|
|
|
9）Imai E, Ito S, Haneda M, et al. Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure). Nephrol Dial Transplant 2015 Jul 6. [Epub ahead of print]
|
|
|
|
|
|
10）Ushigome E, Hamaguchi M, Matsumoto S, et al. Optimal home SBP targets for preventing the progression of diabetic nephropathy in patients with type 2 diabetes mellitus. J Hypertens. 2015; 33: 1853-9
|
|
|
|
|
|
11）Hoshino J, Mise K, Ueno T, et al. A pathological scoring system to predict renal outcome in diabetic nephropathy. Am J Nephrol. 2015; 41: 337-44
|
|
|
|
|
|
12）Mise K, Hoshino J, Ueno T, et al. Clinical and pathological predictors of estimated GFR decline in patients with type 2 diabetes and overt proteinuric diabetic nephropathy. Diabetes Metab Res Rev. 2015; 31: 572-81
|
|
|
|
|
|
13）Mise K, Hoshino J, Ueno T, et al. Clinical implications of linear immunofluorescent staining for immunoglobulin G in patients with diabetic nephropathy. Diabetes Res Clin Pract. 2014; 106: 522-30
|
|
|
|
|
|
14）Moriya T, Suzuki Y, Inomata S, et al. Renal histological heterogeneity and functional progress in normoalbuminuric and microalbuminuric Japanese patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2014; 2: e000029
|
|
|
|
|
|
15）Mise K, Hoshino J, Ueno T, et al. Impact of tubulointerstitial lesions on anaemia in patients with biopsy-proven diabetic nephropathy. Diabet Med. 2015; 32: 546-55
|
|
|
|
|
|
16）Sato E, Amaha M, Nomura M, et al. LDL-apheresis contributes to survival extension and renal function maintenance of severe diabetic nephropathy patients: a retrospective analysis. Diabetes Res Clin Pract. 2014; 106: 241-6
|
|
|
|
|
|
17）Kato S, Maruyama S, Makino H, et al. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial. Clin Exp Nephrol. 2015.doi: 10.1007/s 10157-015-1106-2. PubMed PMID: 25795029
|
|
|
|
|